In this article, we will discuss Midostaurin (Dosage Overview). So, let’s get started.
Acute Myeloid Leukemia
Midostaurin is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation
chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by a FDA approved test.
Limitations of Use
Midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.
Midostaurin is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Select patients for the treatment of AML with Midostaurin based on the presence of FLT3 mutation positivity.
Recommended Dosage in Acute Myeloid Leukemia
The recommended dose of Midostaurin for patients with acute myeloid leukemia is 50 mg orally twice daily with food on Days 8 to 21 of each cycle of induction with cytarabine and daunorubicin and on Days 8 to 21 of each cycle of consolidation with high-dose cytarabine.
Recommended Dosage in ASM, SM-AHN, and MCL
The recommended dose of Midostaurin for patients with ASM, SM-AHN, and MCL is 100 mg orally twice daily with food. Continue treatment until disease progression or unacceptable toxicity occurs.